Value of serum collagen triple helix repeat containing-1(CTHRC1) and 14-3-3η protein compared to anti-CCP antibodies and anti-MCV antibodies in the diagnosis of rheumatoid arthritis

Hu, Tingting; Liu, Y; Tan, Liming; Huang, Jiayi; Yu, Jianlin; Wu, Ying; Pei, Z; Zhang, X; Li, J; Song, Luyan; Dai, Wenbing; Xiang, Yirong

doi:10.1080/09674845.2020.1810400

Cited by 15 publications

(9 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…46 14-3-3η predicts disease activity of RA and its duration, and when combined with other biomarkers such as anti-CCP and RF, its diagnostic ability improves. [25][26][27] This has also been consistent with previous studies. 47 14-3-3η is a predictor of bone remodelling and RA related osteoporosis.…”

Section: Discussionsupporting

confidence: 93%

“…The AUC of 14-3-3η, anti-CCP and RF were 0.81, 0.89 and 0.85 respectively (all P< 0.01). 27 Luedders B, et al, have shown that although the multibiomarker disease activity (MBDA) score moderately correlated with disease activity, it did not predict treatment response to methotrexate. 28 Another study by Baker J et al, demonstrated that adjusted and unadjusted MBDA score correlated similarly with clinical disease activity.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers for the diagnosis and treatment of rheumatoid arthritis-a systematic review

Abdelhafiz¹,

Baker²,

galscow³

2021

Preprint

View full text Add to dashboard Cite

Background Rheumatoid Arthritis (RA) is an autoimmune disease, symmetrically affecting the small joints. Biomarkers are tools that can be used in the diagnosis and monitoring of RA. Aim To systematically explore the role of the biomarkers: C-reactive protein (CRP), Rheumatoid factor (RF), Anti-cyclic citrullinated protein (Anti-CCP), 14-3-3η and the multi-biomarker disease activity (MBDA) score for the diagnosis and treatment of RA. Methods A systematic review of the English literature using four different databases was carried out. Results CRP>7.1 mg/L predicted poor conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) outcome in RA. Anti-CCP, CRP ≥0.3 mg/dL and RF predicted bone erosion and cartilage destruction. Combination of high 14-3-3η with RF and CRP improved the prediction of rapid erosion progression (REP). Anti-CCP was not associated with disease activity, but was associated with increased radiographic damage (r=0.46, p=0.048). RF was not associated with joint damage but correlated with ultrasound-detected bone erosion. 14-3-3η significantly correlated with inflammation, bone remodelling and osteoporosis in RA patients (p<0.05). 14 3 3η positively correlated with RA duration (p=0.003), disease activity and positive RF (P=0.025) and it distinguished early from established RA. Early MBDA scores correlated with later response in disease activity, after 6 and 12 weeks of treatment (p<0.05). MBDA score was able to differentiate between small differences in disease activity and predicted remission over one year period. Conclusion The investigated biomarkers are helpful tools in clinical practice for diagnosis, monitoring of treatment and predicting prognosis in RA patients. However, further research is still required to investigate novel biomarkers for the pre-treatment selection of potentially responsive patients before starting therapy for a precision medicine in this area.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Resultsmentioning

confidence: 99%

Biomarkers for the diagnosis and treatment of rheumatoid arthritis-a systematic review

Abdelhafiz¹,

Baker²,

galscow³

2021

Preprint

View full text Add to dashboard Cite

show abstract

“…In their work, Myngbay et al 15 recognized CTHRC1 as a sensitive and feasible marker for diagnosis of RA. Furthermore, Hu et al 16 suggested that adding CTHRC1 to anti-CCP can improve the diagnosis of RA. Similar conclusions were reported by Selim et al 17 In our work, comparative and correlation analysis identified a strong relation between CTHRC1 levels and disease activity in RA patients in accordance with previous reports.…”

Section: Discussionmentioning

confidence: 99%

Serum Collagen Triple Helix Repeat Containing-1 Levels are Related to Radiological Affection and Disease Activity in Rheumatoid Arthritis

Nassef¹,

Elabd²,

Elzomor³

et al. 2022

OARRR

View full text Add to dashboard Cite

Background Rheumatoid arthritis (RA) is a common systemic inflammatory disease. Collagen triple helix repeat containing-1 (CTHRC1) is a unique gene product able to reduce collagen deposition. The present study aimed to assess CTHRC1 level in RA patients and to uncover its relation to clinical, laboratory and radiological findings. Methods The study included 60 adult RA patients. In addition, there were 60 control subjects who included patients with osteoarthritis (n = 20) and reactive arthritis (n = 20) and healthy controls (n = 20). Serum CTHRC1 levels were assessed by Enzyme-Linked Immunosorbent Assay (ELISA). Disease activity was calculated using the Disease Activity Score (DAS28-CRP). Radiological damage was evaluated using the Simple Erosion Narrowing Score (SENS). Results There was significantly higher serum CTHRC1 levels in RA patients when compared to OA, ReA and control groups [median (IQR): 4.66 (1.68–11.7) versus 1.88 (1.14–2.94), 1.55 (0.98–3.15) and 1.14 (0.85–1.3) mg/dL, respectively, p < 0.001]. There was significantly higher CTHRC1 levels in patients with higher disease activity [median (IQR): 2.23 (1.4–4.73) versus 6.55 (4.66–12.0) mg/dL, p = 0.004]. Patients with higher SENS had significantly higher CTHRC1 [median (IQR): 1.99 (1.4–4.66) versus 9.75 (4.39–12.63) mg/dL, p < 0.001] and DAS28 [median (IQR): 4.25 (2.9–5.2) versus 5.4 (4.65–5.8), p = 0.01]. Conclusion Serum CTHRC1 levels are related to disease severity and radiological affection in RA patients.

show abstract

“…CTHRC1 also correlated significantly with RA disease activity based on the combined index of the 28-joint disease activity score (DAS28), the combined score DAS28-CRP, and with a panel of pro-inflammatory cytokines, including interleukin 1 beta (IL-1β), interleukin 6 (IL-6), interleukin 8 (IL-8) and interferon gamma (IFNγ) [ 7 ]. A recent study independently confirmed that CTHRC1 is a specific marker for the diagnosis of RA, particularly when used in combination with other markers, such as anti-mutated citrullinated vimentin antibodies (anti-MCV) [ 8 ]. Together, these findings corroborate observations in murine models of arthritis and indicate that CTHRC1 may have potential use as a biomarker for enhanced differential RA diagnosis.…”

Section: Cthrc1 Is Associated With Ra Development and Disease Sevementioning

confidence: 99%

“…Nonetheless, neither of these two markers has sufficient specificity or sensitivity for effective diagnosis of all RA patients, and neither autoantibody allows classification of patient subpopulations or patient outcome [ 6 ]. Recently, CTHRC1 has emerged as a new biomarker that may contribute to improved RA diagnosis and assessment of disease activity [ 7 , 8 ]. CTHRC1 protein levels are increased in the plasma of RA patients but were either absent or detected only at very low levels in healthy individuals or patients suffering from other forms of arthritis, such as OA or reactive arthritis (ReA) [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

The Role of Collagen Triple Helix Repeat-Containing 1 Protein (CTHRC1) in Rheumatoid Arthritis

Myngbay

Manarbek

Ludbrook

et al. 2021

IJMS

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic autoimmune disease causing inflammation of joints, cartilage destruction and bone erosion. Biomarkers and new drug targets are actively sought and progressed to improve available options for patient treatment. The Collagen Triple Helix Repeat Containing 1 protein (CTHRC1) may have an important role as a biomarker for rheumatoid arthritis, as CTHRC1 protein concentration is significantly elevated in the peripheral blood of rheumatoid arthritis patients compared to osteoarthritis (OA) patients and healthy individuals. CTHRC1 is a secreted glycoprotein that promotes cell migration and has been implicated in arterial tissue-repair processes. Furthermore, high CTHRC1 expression is observed in many types of cancer and is associated with cancer metastasis to the bone and poor patient prognosis. However, the function of CTHRC1 in RA is still largely undefined. The aim of this review is to summarize recent findings on the role of CTHRC1 as a potential biomarker and pathogenic driver of RA progression. We will discuss emerging evidence linking CTHRC1 to the pathogenic behavior of fibroblast-like synoviocytes and to cartilage and bone erosion through modulation of the balance between bone resorption and repair.

show abstract

Value of serum collagen triple helix repeat containing-1(CTHRC1) and 14-3-3η protein compared to anti-CCP antibodies and anti-MCV antibodies in the diagnosis of rheumatoid arthritis

Cited by 15 publications

References 14 publications

Biomarkers for the diagnosis and treatment of rheumatoid arthritis-a systematic review

Biomarkers for the diagnosis and treatment of rheumatoid arthritis-a systematic review

Serum Collagen Triple Helix Repeat Containing-1 Levels are Related to Radiological Affection and Disease Activity in Rheumatoid Arthritis

The Role of Collagen Triple Helix Repeat-Containing 1 Protein (CTHRC1) in Rheumatoid Arthritis

Contact Info

Product

Resources

About